Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

April 12, 2021

Study Completion Date

September 30, 2023

Conditions
Oral CancerInduction ChemotherapyProgrammed Cell Death 1 InhibitorInductive Therapy
Interventions
DRUG

Toripalimab

Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22

DRUG

Paclitaxcel

Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22

DRUG

Cisplatin

Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22

PROCEDURE

Radical surgery

Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.

RADIATION

Post-operative radiotherapy/chemoradiotherapy

Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.

Trial Locations (1)

Unknown

Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT04473716 - Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients | Biotech Hunter | Biotech Hunter